Akeso Inc. has announced the enrollment of the first patient in its Phase III clinical trial (AK112-312/HARMONi-GI6) evaluating the efficacy of ivonescimab as a first-line treatment for advanced metastatic colorectal cancer. This trial is a pivotal step in addressing the unmet clinical needs for patients with this condition. Previous Phase II data, presented at the 2024 European Society for Medical Oncology Congress, demonstrated promising anti-tumor activity of ivonescimab in combination with chemotherapy, showing an overall response rate of 81.8% and a disease control rate of 100%. The ongoing Phase III trial aims to further validate these findings and potentially offer a novel immunotherapy treatment option for patients with microsatellite stable or proficient mismatch repair-type metastatic colorectal cancer, a group representing up to 95% of such cases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.